Hepatitis C: Analysis of key marketed products.
By Michael Haydock, Lead Analyst
27 August 2014
I am the Lead Analyst of the immunology and inflammation and infectious diseases and vaccines teams at Datamonitor Healt...
Read full bio
When launched in 2011, both Incivek and Victrelis delivered strong improvements in efficacy over the standard therapy and also reduced treatment duration. However, due to the poor side-effect profiles and inconvenient dosing schedules of both drugs, they have been rapidly superseded by Sovaldi.
Datamonitor Healthcare has produced an in-depth analysis of marketed drugs for hepatitis C in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK), including an assessment of product positioning in the face of pipeline competition and an evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.
How will our hepatitis C marketed drugs report benefit you?
- Overcome current marketed drugs issues
Recognize the issues faced by established marketed drugs Incivek and Victrelis and how newly launched brands such as Sovaldi have overcome these issues, allowing you to gauge how physician expectations of new launches have changed.
- Benchmark your product
Explore the ways in which Sovaldi is making a substantial advance in hepatitis C treatment and how it has received its gold-standard status, enabling you to compare your brand to that which is the most successful in the market.
- Assess pipeline threats
Understand how product positioning could change in the face of pipeline competition through our assessments, and evaluate clinical and commercial drug attributes to determine the potential threats emerging from the pipeline.
Key questions answered
- Why has Sovaldi achieved unprecedented blockbuster sales?
- How do other marketed drugs compare to Sovaldi?
- Which brands occupy the dominant market share in each genotype?
|Drug List:||Companies Mentioned:|
Posted in Infectious Diseases.